A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data [0.03%]
来那度胺和硼替佐米联合地塞米松与标准治疗在中国多发性骨髓瘤初治患者中的成本效益分析：基于真实世界数据的研究
Adam Irving,Dennis Petrie,Anthony Harris et al.
Adam Irving et al.
Background and objective: Health technology assessments traditionally rely on clinical trial data, leaving uncertainties about real-world cost effectiveness. This post-market economic evaluation used registry data to esti...
Comparing the Influence of Heterogeneity on Model Outcomes in Individual-Level and Cohort Simulations: An Exploratory Simulation Study [0.03%]
一项探索性仿真研究：比较个体水平和队列仿真中异质性对模型结果影响的差异
Evelien B van Well,Tim M Govers,Hendrik Koffijberg
Evelien B van Well
Introduction: When developing health economic simulation models, individual-level and cohort state-transition model types are commonly used. However, heterogeneity and the extent to which it is taken into account is thoug...
Cure Models: What is Meant by a Survival 'Plateau', and Do Experts Agree on What Constitutes One? [0.03%]
治愈模型：生存的“平台期”意味着什么？专家对此达成共识了吗？
Dan Jackson,Michael Sweeting,Robert Hettle et al.
Dan Jackson et al.
Background: Cure models are becoming more popular for modelling survival data where long-term survival, or 'cure', is considered plausible. One criterion for considering fitting cure models is evidence for a plateau in th...
Patient-Level Health Economic Modeling in Excel Without VBA: A Tutorial [0.03%]
基于Excel的卫生经济学模型模拟教学无需VBA编程
Rob Blissett,Will Sullivan,Inola Subban et al.
Rob Blissett et al.
Cohort-level models in Microsoft Excel® remain the standard for cost-effectiveness modeling to inform health technology assessment (HTA), despite calls and rationale for more flexible approaches. Their limited ability to capture patient-le...
The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment [0.03%]
视角对EQ-5D-Y-3L估值的影响：使用OPUF工具和离散选择实验进行比较研究
Jake Hitch,Gayathri Kumar,Paul Schneider et al.
Jake Hitch et al.
Background: The choice of perspective in valuation tasks is likely to affect the scale of EQ-5D-Y-3L value sets, but less is known about how it affects the relative importance of different dimensions. ...
Xiaoyu Zhang,Jiaru Liu,Zhengwei Wang et al.
Xiaoyu Zhang et al.
Background and objective: Inflammatory arthritis is a common condition treated in rheumatology clinics, contributing significantly to healthcare costs and societal burden. Understanding the economic impact of inflammatory...
Scoping Review of Productivity-Adjusted Life Years (PALYs): Methods, Applications and Policy Implications [0.03%]
以工效调整生命年（PALY）为主题的系统评价：方法、应用及政策含义
Zanfina Ademi,Dina Abushanab,Maria J Alfonso Arvez et al.
Zanfina Ademi et al.
Objective: To understand the application of productivity-adjusted life years (PALYs) as an outcome measure across various disease contexts. Methods: ...
Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies [0.03%]
基于多国研究范围审查数据探索外国成本效益分析对西班牙的适用性
Lidia García-Pérez,Ignacio Abásolo-Alessón,Miguel Ángel Negrín-Hernández
Lidia García-Pérez
Objective: This study examines the generalizability of foreign economic evaluations to the Spanish healthcare system. The research aims to describe the cross-country adaptation methods identified in a scoping review of mu...
Eladocagene Exuparvovec for the Treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd): An Economic Evaluation from a US Perspective [0.03%]
评估芳香族L-氨基酸脱羧酶缺乏症（AADC缺乏症）治疗药物Eladocagene exuparvovec的经济性——美国视角
Rongrong Zhang,Thomas O&#x;Connell,Berrin Monteleone et al.
Rongrong Zhang et al.
Background: Recently, the gene therapy eladocagene exuparvovec received accelerated approval from the US Food and Drug Administration (as eladocagene exuparvovec-tneq) for treatment of aromatic L-amino acid decarboxylase ...
Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy [0.03%]
意大利碳青霉烯耐药肠杆菌科感染新药 azi-trionam/avibactam与多粘菌素+美罗培南治疗金属β-内酰胺酶(NDM、KPC)-produceing肠杆菌的 cost-effectiveness分析
Marco Falcone,Xiyu Bao,Fionn Woodcock et al.
Marco Falcone et al.
Background and objective: Aztreonam-avibactam (ATM-AVI) is a novel combination antibiotic approved in Europe for the treatment of complicated intra-abdominal infection, hospital-acquired pneumonia, including ventilator-as...